Home

Michele Reni

Request an appointment

Specialty:

Oncology Pancreatic Cancer Pancreatic Surgery Gastrointestinal Diseases Gastrointestinal Cancers Brain and CNS Cancer

Profession:

Oncologist

Location:

Department of Clinical Oncology @ Ospedale San Raffaele

Languages:

Request an appointment

Biography

Prof. Michele Reni is Head of the Oncology and Oncology Day Hospital Units, Director of the strategic clinical coordination program of the Pancreas Center at IRCCS Ospedale San Raffaele, and Associate Professor of Oncology at the University Vita e Salute.

He is responsible for research and outpatient activities focused on the treatment of pancreatic tumors at the Oncology Unit directed by Prof. Stefano Cascinu. He is a member of the Cancer Center Board at IRCCS San Raffaele and a member of the Working Group on pancreatic cancer issues of the General Directorate of Welfare of the Lombardy Region.

He graduated from the Faculty of Medicine and Surgery of the University of Milan in 1988, specialized in Radiation Therapy in 1992 and received a second specialization in Medical Oncology in 1996.

Both clinically and in research, Dr Reni is interested in the treatment of pancreatic, nervous system, gastric and oesophageal tumours. In particular, his main contribution has been to co-ordinate more than 20 independent studies that have led to changes in standard therapy for pancreatic cancer.

He is the coordinator of the pancreatic cancer treatment guidelines and the drafter of the central nervous system tumor treatment guidelines of the Italian Association of Medical Oncology. He is also the member of the Board of Directors of the Italian Association for the Study of the Pancreas (AISP).

He has authored and co-authored more than 250 publications in peer-reviewed journals and book chapters. His Hirsch index is 58. He regularly participates as a lecturer in national and international industry congresses.

Education

University of Milan
Degree in Medicine and Surgery - 1988

University of Milan
Specialization in Radiotherapy - 1992

University of Milan
Specialization in Medical Oncology - 1996

Do you need an appointment?

Request an appointment

Publications

Latest publications

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.

Br J Cancer. 2016 Jul 26;115(3):290-6.

Reni M, et al.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Lancet Oncol. 2016 17 (11): 1521- 1532.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe

Health-related quality of life in patients with high-risk lowgrade glioma (EORTC 22033-26033): a randomised, openlabel, phase 3 intergroup study.

Lancet Oncol. 2016; 17 (11): 1533-1542

Reijneveld JC, Taphoorn MJ, Coens C, Bromberg JE, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG

What treatment in 2017 for inoperable pancreatic cancers?

Ann Oncol. 2017

Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M.

Central nervous system gliomas. Crit Rev Oncol Hematol.

2017 May;113:213-234

Reni M, Mazza E, Zanon S, Gatta G, Vecht CJ

Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.

Ann Oncol. 2017;28(11):2786-2792

Reni M, et al.

Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.

Cancer Treat Rev. 2017;60:32-43

Chiaravalli M, Reni M, O'Reilly EM.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Lancet Oncol. 2018 Mar;19(3):e151-e160

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Oldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423.

Reni M, et al

Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.

Semin Oncol. 2018 Jun;45(3):107-115.

Zhen DB, Coveler A, Zanon S, Reni M, Chiorean EG

Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.

Lancet Gastroenterol Hepatol. 2018;3(10):691-697

Reni M, et al

A randomised phase 2 trial of nabpaclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.

Eur J Cancer. 2018;102:95-102

Reni M, et al

Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.

Cancer Treat Rev. 2019;72:1-6.

Macchini M, Chiaravalli M, Zanon S, Peretti U, Mazza E, Gianni L, Reni M.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

NEJM 2019

Golan T, Hammel P, Reni M, et al

Do you need an appointment?

Request an appointment